Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
The partnership between Novo Nordisk and GoodRx represents a fundamental shift in how pharmaceutical companies reach patients. By bypassing traditional insurance channels, drugmakers are creating direct-to-consumer models that could unlock significant growth opportunities whilst improving patient access to essential medications.
What You Need to Know
This group focuses on companies positioned to benefit from the growing trend of pharma-digital health collaborations. It includes pharmaceutical giants pioneering these strategies, digital health platforms providing consumer infrastructure, and medical technology firms in related treatment ecosystems like diabetes care.
Why These Stocks
These stocks were handpicked by professional analysts based on their strategic positioning in the evolving healthcare landscape. Each company offers tactical exposure to the transformation happening as pharmaceutical companies embrace digital platforms to expand market reach and improve drug affordability.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+241.65%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 241.65% over the next year.
Stocks Rated Buy by Analysts
13 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Revolutionary Healthcare Shift
The Novo Nordisk-GoodRx partnership signals a fundamental transformation in how pharmaceutical companies reach patients. This direct-to-consumer approach could become the new standard, creating massive opportunities for early movers.
Bypassing Traditional Barriers
These companies are pioneering ways to make expensive medications more accessible by cutting out insurance middlemen. This trend could unlock billions in previously untapped market potential.
Digital Health Gold Rush
As more pharmaceutical giants embrace digital platforms, the companies facilitating these partnerships are positioned for explosive growth. You're looking at the infrastructure of tomorrow's healthcare system.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Big Tech's Nuclear Bet: Powering The AI Revolution
Google's partnership to build a small modular nuclear reactor highlights a pivotal shift in powering AI infrastructure. This theme focuses on the companies enabling the next generation of nuclear energy to meet Big Tech's surging electricity demands.
Frequently Asked Questions
Everything you need to know about the product and billing.